Qompium NV was founded in 2014 as one of the first digital health companies in Europe. Since initiation, they focused on the development of FibriCheck, a medical application to detect and follow-up multiple cardiac arrhythmia (including Atrial Fibrillation) based on PPG signals – a technology commonly found in smartphones, smartwatches and other wearables. FibriCheck is today approved as a medical device across different geographical regions (US (FDA)/EU/Australia/Middle-East/Singapore) and has proven substantial equivalent accuracy levels compared to the golden standard (ECG).
FibriCheck has been used by almost 1.000.000 people. The solution is offered as an end-to-end solution to hospitals (telemonitoring of both high-risk and chronic patients) and directly to consumers. On top, FibriCheck recently started to license its algorithms to other companies (telemonitoring companies, wearable providers, …) who can build on our regulatory approvals to offer cardiac arrhythmia analysis to their end users.